FDA Advisers Back First mRNA Flu Vaccine for Older Adults
Federal vaccine advisers have recommended Moderna’s MFLUSIVA review, moving the first mRNA influenza vaccine closer to possible U.S. approval for adults 50 and older before the coming winter flu season. The vote came from the FDA’s independent vaccine advisory panel, which reviewed safety and effectiveness data for MFLUSIVA, an influenza vaccine made by Moderna. The…







